1[1]Renstrom E,Barg S,Thevenod F,et al.Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channelindependent action[J].Diabetes,2002,51(suppl 1):s33.
2[2]Renstrom E,Barg s,Thevenod F,et al.Sulfonylurea_mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action[J].Diabetes,2002,51 (Suppl 1):S33-S36
3[4]Muller G.Dynamics of plasma membrance microdomains and crosstalk to the insulin signalling cascade[J].FEBS Lett,2002,531:81.
4[5]CroopL C,Pelkonen R,Koskimies S,et al.Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes[J].Diabetes Care,1986,9:129.
5[6]U K Prospective Diabetes Study(UKPDS) Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J].Lancet,1998,352:837.
6[7]Menger C,Ione K,William C,et al.Pharmacokinetics and pharmacodynamics of extended-release Glipizide GITS compared with immediate-release Glipide in patients with Type 2 diabetes Mellitus[J].Journal of Clinical Pharmacology,2002,42:651.
8[9]Egbaria K,Ramachandnm C,Weiner N.Topical application of liposomally entrapped cyclosporin ivaluated by in vitro diffusion studies with human skin[J].Skin Pharmacol,1991,4(1):21.
9[10]Morley JE,Perry HM.The management of diabetes mellitusin older individuals[J].Drugs,1991,41:548.
10[11]Rydberg T,Roder M,Jonsson A,et al.Hypoglycemic activity of glyburide(glibenclamide) metabolites in humans[J].Diabetes Care,1994,17:1026.
4Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes [ J ]. N Engl J Med, 2008,358: 2545 - 2559.
5Effect of intensive blood-glucose control with mefformin on complications in overweight patients with type 2 diabetes ( UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group[ J ]. Lancet, 1998,352: 854 - 865.
6Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes [ J ]. N Engl J Med, 2008,359: 1577 - 1589.
7Goldberg RB, Temprosa M, Hafner S, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group [J]. Diabetes Care, 2009,32: 726 - 732.
8Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus[ J]. Cochrane Database Syst Rev, 2006,CD002967.
9Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) [ J]. Eur Heart J, 2007,28: 88 - 136.
10Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [J]. Lancet, 2006,368:1096 - 1105.
